Skip to main
ABT

Abbott Labs (ABT) Stock Forecast & Price Target

Abbott Labs (ABT) Analyst Ratings

Based on 18 analyst ratings
Buy
Strong Buy 44%
Buy 44%
Hold 11%
Sell 0%
Strong Sell 0%

Bulls say

Abbott Laboratories is well positioned to capitalize on the global growth of the cardiovascular and diabetes device markets, thanks to its diverse portfolio of high-quality products and its focus on expanding its presence in key regions outside of the United States. The company's innovative commercial strategy, supported by a competitive portfolio and a focus on affordability, should continue to drive market share gains in the rapidly growing electrophysiology market. Additionally, Abbott's diversified business model, strong financials and ongoing success in launching new products make it a compelling investment opportunity.

Bears say

Abbott Laboratories is facing a number of challenges, including rapid technological changes and intense competition in the medical devices and diagnostics market. Despite the company's investments in new product launches and expanding its biosimilars portfolio, the negative impact of a weaker-than-expected respiratory season and lower growth expectations in several key business segments may hinder its ability to sustain its growth trajectory and meet its sales outlook. With global sales accounting for a significant portion of revenue, Abbott may also face currency fluctuations and other macroeconomic risks that could negatively affect its financial performance.

Abbott Labs (ABT) has been analyzed by 18 analysts, with a consensus rating of Buy. 44% of analysts recommend a Strong Buy, 44% recommend Buy, 11% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Abbott Labs and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Abbott Labs (ABT) Forecast

Analysts have given Abbott Labs (ABT) a Buy based on their latest research and market trends.

According to 18 analysts, Abbott Labs (ABT) has a Buy consensus rating as of Jun 26, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $127.83, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $127.83, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Abbott Labs (ABT)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.